News und Analysen

As an old investing adage goes: Investors have lost more reaching for yield than at the point of a gun. That may sound a bit dramatic, but when you think of all the yield trap stocks -- high-yield

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.

Innovative biopharmaceutical company Metsera (NASDAQ: MTSR) has been climbing all year. It went public on Feb. 3 of this year, priced at $18 per share, and immediately climbed above $27. It had been

On Tuesday, Amgen (NASDAQ: AMGN) stock hit its one-year high, on continued momentum from a far better-than-expected quarterly earnings report. The immediate catalyst was a post-earnings price target

The next three years have just become a bigger question mark for Pfizer (NYSE: PFE) than they were before. There are two competing factors taking shape, one internal to the drugmaker; the other is

As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all

A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give investors

UnitedHealth Group (NYSE: UNH) used to be a safe stock to hang on to. Its financials looked impressive, the business got bigger, it boosted its dividend, and it looked like a no-brainer stock to

A $5,000 investment may not seem like a large amount of money to invest in the stock market. But you can make the most of it by investing for the long haul, and picking modestly valued growth

The stock market caters to investors with almost any budget, especially with online brokers offering commission-free trading and fractional shares. Even with a modest sum, you can find quality

The stock market is near all-time highs as Wall Street chugs through earnings season and eyes the end of the year just around the corner.

But not all stocks are hitting new heights. Some prominent

Income investors usually don't mind too much if a stock doesn't deliver tremendous gains, as long as it keeps the dividends flowing. They typically don't like it when a stock tumbles, though, as

Dividend yields are more than just an indication of how much income a stock will generate for investors. High yields are often a sign that a stock is trading hands at an attractive price point. When

One of the healthier stocks in the healthcare field Wednesday was Amgen (NASDAQ: AMGN). The biotech and pharmaceutical company published its third-quarter results the previous day after market

Shares in Viking Therapeutics (NASDAQ: VKTX) rose by a whopping 44.9% in October, according to data provided by S&P Global Market Intelligence. The move occurred in three legs, and each one was

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly

Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor Merck

Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook. Scooping up shares of great companies after they have experienced

Pfizer (NYSE: PFE) is one of the oldest and most respected pharmaceutical companies in the world. The stock is out of favor right now, trading down around 60% from its 2022 high-water mark. The

I can think of more than a few reasons why someone might want to invest in Pfizer (NYSE: PFE), the pharmaceutical giant. The best one, for me at the moment, is its huge dividend yield -- 7% as of

I don't like the term "growth stock" all that much. Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that textbook growth stocks

Dividends are one of investors' most powerful tools for earning strong returns over the long run. Buying shares of strong dividend-paying companies and reinvesting the payout allows compounding to

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and

AbbVie's (NYSE: ABBV) products are regularly used to help heal the sick, but the company's stock wasn't healthy for portfolios on Friday. The company published its latest quarterly earnings release